Editas Medicine Inc share price logo

Editas Medicine Inc

NASDAQ: EDIT

Small Cap

$3.17

+0.13

(+4.28%)

as on

Editas Medicine Inc Stock Performance

as on May 7, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $3.04
    $3.18
    downward going graph

    4.10%

    Downside

    0.32%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $1.29
    $4.54
    downward going graph

    59.31%

    Downside

    43.13%

    Upside

    downward going graph

Editas Medicine Inc share price movements today

Previous Close
$3.04
Open
$3.10
Volume
1.6M
Day's Low - High
$3.04 - $3.18
52 Week Low - High
$1.29 - $4.54

Editas Medicine Inc Historical Returns

1 Month Return
+ 11.76 %
3 Month Return
+ 67.03 %
1 Year Return
+ 128.57 %
3 Year Return
-68.88 %
5 Year Return
-91.15 %

Editas Medicine Inc Stock Fundamentals & Key Indicators

Check Editas Medicine Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$293.7M

EPS (TTM)

-1.0488

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-94.1M

Revenue (TTM)

40.5M

Profit Margin

0.00%

Return On Equity TTM

-198.14%

Editas Medicine Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Editas Medicine Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$293.7M-91.15%NA0.00%
BUY$40.2B127.94%75.8512.55%
BUY$107.9B99.08%25.1832.94%
NA$33.1BNA120.445.37%
BUY$73.6B40.83%17.1329.65%

Stock Returns calculator for Editas Medicine Inc Stock including INR - Dollar returns

The Editas Medicine Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Editas Medicine Inc investment value today

Current value as on today

₹2,67,480

Returns

₹1,67,480

(+167.48%)

Returns from Editas Medicine Inc Stock

₹1,38,346 (+138.35%)

Dollar Impact

₹29,134 (+29.13%)

Analyst Recommendation on Editas Medicine Inc Stock

Based on 24 analysts

BUY

54.17%

Buy

41.67%

Hold

4.17%

Sell

Based on 24 analysts, 54.17% of analysts recommend a 'BUY' rating for Editas Medicine Inc. Average target price of $5.72

Editas Medicine Inc Share Price Target

Get share price movements and forecasts by analysts on Editas Medicine Inc.

What analysts predicted

44.58%UPSIDE

Target Price

$5.72

Current Price

$3.17

Analyzed by

24 Analysts

Target

$5.72

Editas Medicine Inc target price $5.72, a slight upside of 44.58% compared to current price of $3.17. According to 24 analysts rating.

Indian Investors' Interest in Editas Medicine Inc Stock

Search interest for Editas Medicine Inc Stock has decreased by -7% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-7% versus previous 30 day period

Editas Medicine Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
5
60
1
0
0
30
4
3
7
24
Gross Profit
3
58
0
0
-1
30
4
3
7
24
Operating Income
-50
-23
-66
-71
-65
-46
-76
-51
-24
-14
EBITDA
-48
-22
-65
-70
-60
-32
-71
-49
-21
-5
Interest Expense
-
3
-
-
-
-
2
2
2
6
Depreciation
1
1
1
1
1
1
1
1
0
0
Income Before Tax
-45
-18
-61
-67
-62
-45
-76
-53
-25
-5
Income Tax Expense
-1
10
0
-
1
-
-
-
-
-
Net Income
-45
-18
-61
-67
-62
-45
-76
-53
-25
-5
Net Profit Margin
-843.68%
-31.43%
-5458.15%
-13178.75%
-101870.49%
-148.33%
-1633.49%
-1487.84%
-332.98%
-22.72%

Editas Medicine Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
6
13
31
20
90
25
19
78
32
40
Gross Profit
-50
-69
-58
-76
90
25
19
72
32
40
Operating Income
-97
-119
-113
-140
-134
-193
-225
-169
-251
-99
EBITDA
-96
-116
-110
-138
-130
-188
-219
-163
-233
-148
Interest Expense
0
0
3
7
2
5
4
-
2
6
Depreciation
-
2
3
2
3
5
6
6
5
5
Income Before Tax
-97
-120
-109
-133
-115
-192
-220
-153
-237
-160
Income Tax Expense
-1
-1
-3
-10
-6
-7
-16
5
-
-
Net Income
-97
-120
-109
-133
-109
-185
-204
-153
-237
-160
Net Profit Margin
-1605.53%
-876.49%
-344.28%
-651.43%
-120.59%
-724.66%
-1036.69%
-196.13%
-733.72%
-395.01%

Editas Medicine Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-18
-61
-67
-62
-45
-76
-53
-25
-5
Operating Cash Flow
-22
-49
-57
-52
-50
-47
-50
-30
-36
Investing Cash Flow
62
-4
51
83
30
56
42
39
0
Financing Cash Flow
0
0
0
-
55
-1
7
17
17
Change in Cash
41
-54
-4
31
35
7
0
25
-19

Editas Medicine Inc Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-120
-109
-133
-115
-192
-220
-153
-237
-160
Operating Cash Flow
-9
-45
-40
-179
-163
-177
-132
-210
-165
Investing Cash Flow
-183
-53
12
-140
-54
114
-3
162
138
Financing Cash Flow
154
86
131
224
282
1
118
56
40
Change in Cash
-38
-11
103
-96
63
-61
-17
7
13

Global Institutional Holdings in Editas Medicine Inc

Funds
Holdings
AQR Capital Management LLC
0.66%
JPMorgan Chase & Co
1.68%
BlackRock Inc
9.55%
Citadel Advisors Llc
0.71%
Renaissance Technologies Corp
3.11%

Insights on Editas Medicine Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 3.57M → 24.74M (in $), with an average increase of 61.0% per quarter

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, EDIT has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, EDIT stock has moved up by 67.0%

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 4 quarters, -76.08M → -5.62M (in $), with an average increase of 167.3% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Editas Medicine Inc. has experienced a drawdown of -68.9%, however Alnylam Pharmaceuticals, Inc. resisted the overall trend and outperformed by 61.0%

About Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
OrganisationEditas Medicine Inc
Headquarters11 Hurley Street, Cambridge, MA, United States, 02141
IndustryBiotechnology
CEODr. Gilmore O'Neill M.D.
E-voting on sharesClick here to vote

Key Management of Editas Medicine Inc

Name

Title

Dr. Gilmore O'Neill M.D.

President, CEO & Director

Mr. Damien Grierson J.D.

Senior VP, General Counsel & Corporate Secretary

Mr. Tom Love

Vice President of People

Mr. Frank Panaccio

Senior VP & Chief Business Officer

Ms. Brieana Buckley

Senior Vice President of Development and Program Leadership

FAQs

What is Editas Medicine Inc share price today?

Editas Medicine Inc share price today is $3.17 as on at the close of the market. Editas Medicine Inc share today touched a day high of $3.18 and a low of $3.04.

What is the 52 week high and 52 week low for Editas Medicine Inc share?

Editas Medicine Inc share touched a 52 week high of $4.54 on and a 52 week low of $1.29 on . Editas Medicine Inc stock price today i.e. is closed at $3.17,which is 30.13% down from its 52 week high and 145.74% up from its 52 week low.

What is Editas Medicine Inc's market capitalisation today?

Editas Medicine Inc market capitalisation is $0.00T as on .

How to invest in Editas Medicine Inc Stock (EDIT) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Editas Medicine Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Editas Medicine Inc Shares that will get you 0.4732 shares as per Editas Medicine Inc share price of $3.17 per share as on May 7, 2026 at 1:29 am IST.

What is the minimum amount required to buy Editas Medicine Inc Stock (EDIT) from India?

Indian investors can start investing in Editas Medicine Inc (EDIT) shares with as little as ₹94.61 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹946.10 in Editas Medicine Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Editas Medicine Inc share’s latest price of $3.17 as on May 7, 2026 at 1:29 am IST, you will get 3.1546 shares of Editas Medicine Inc. Learn more about fractional shares .

What are the returns that Editas Medicine Inc has given to Indian investors in the last 5 years?

Editas Medicine Inc stock has given -91.15% share price returns and 29.19% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?